Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 9/20 | 0.64 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 7/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9565402 | 1.00 | MME (0.64) | MMEMMEL1ACEFFAR1 | |
| SCHEMBL17580886 | 0.87 | MME (0.53) | MMEMMEL1ACE | |
| SCHEMBL28578516 | 0.80 | MME (0.65) | MMEMMEL1ACE | |
| SCHEMBL18555598 | 0.79 | FFAR1 (0.57) | MMEMMEL1ACEFFAR1 | |
| SCHEMBL9565421 | 0.78 | MME (1.00) | MMEMMEL1ACE | |
| SCHEMBL7438041 | 0.77 | MME (0.59) | MMEMMEL1ACE | |
| SCHEMBL29007017 | 0.77 | MME (0.65) | MMEMMEL1ACE | |
| SCHEMBL10710074 | 0.74 | CPA3 (0.67) | MMEACEFFAR1 | |
| SCHEMBL1912584 | 0.72 | MME (0.80) | MMEMMEL1ACE | |
| SCHEMBL2878301 | 0.72 | MME (0.80) | MMEMMEL1ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11434192-B2 | Process and intermediates | NOVARTIS AG (CH) | 2022-09-06 | — | — | US | claimed |
| EP-3481799-A1 | NEW PROCESS FOR EARLY SACUBITRIL INTERMEDIATES | Novartis AG (CH) | 2019-05-15 | — | — | EP | claimed |
| EP-2890672-B1 | PROCESSES FOR PREPARING INTERMEDIATES FOR THE MANUFACTURE OF NEP INHIBITORS | NOVARTIS AG (CH) | 2018-05-30 | — | — | EP | claimed |
| WO-2018007919-A1 | NEW PROCESS FOR EARLY SACUBITRIL INTERMEDIATES | NOVARTIS AG (CH) | 2018-01-11 | — | — | WO | claimed |
| WO-2017051326-A1 | NEW PROCESSES AND INTERMEDIATES USEFUL IN SYNTHESIS OF NEP INHIBITORS | NOVARTIS AG (CH) | 2017-03-30 | — | — | WO | claimed |
| EP-2609071-B1 | NEW PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE MANUFACTURE OF NEP INHIBITORS | NOVARTIS AG (CH) | 2016-09-21 | — | — | EP | claimed |
| EP-2609075-B1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES FOR THE MANUFACTURE OF NEP INHIBITORS | NOVARTIS AG (CH) | 2016-03-16 | — | — | EP | claimed |
| US-9085529-B2 | Process for the preparation of intermediates useful for the manufacture NEP inhibitors | NOVARTIS AG (CH) | 2015-07-21 | — | — | US | claimed |
| EP-2609071-A1 | NEW PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE MANUFACTURE NEP INHIBITORS | Novartis AG (CH) | 2013-07-03 | — | — | EP | claimed |
| US-20130158275-A1 | NEW PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE MANUFACTURE NEP INHIBITORS | NOVARTIS AG (CH) | 2013-06-20 | — | — | US | claimed |
| WO-2012025502-A1 | NEW PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE MANUFACTURE NEP INHIBITORS | NOVARTIS AG (CH) | 2012-03-01 | — | — | WO | claimed |
| EP-0555175-A1 | Biaryl substituted 4-amino-butyric acid amides | CIBA-GEIGY AG (CH) | 1993-08-11 | — | — | EP | claimed |
| CN-108602785-B | Novel processes and intermediates | 诺华股份有限公司 | 2023-08-11 | — | — | CN | disclosed |
| US-11434192-B2 | Process and intermediates | NOVARTIS AG (CH) | 2022-09-06 | — | — | US | disclosed |
| EP-3386955-B1 | INTERMEDIATES FOR THE PREPARATION OF SACUBITRIL AND THEIR PREPARATION | NOVARTIS AG (CH) | 2020-08-05 | — | — | EP | disclosed |
| CN-107250100-B | process and intermediates for preparing NEP inhibitors | 诺华股份有限公司 | 2019-12-06 | — | — | CN | disclosed |
| US-20130158285-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES FOR THE MANUFACTURE OF NEP INHIBITORS | NOVARTIS AG (CH) | 2013-06-20 | — | — | US | disclosed |
| WO-2012025501-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES FOR THE MANUFACTURE OF NEP INHIBITORS | NOVARTIS AG (CH) | 2012-03-01 | — | — | WO | disclosed |
| WO-2012025502-A1 | NEW PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE MANUFACTURE NEP INHIBITORS | NOVARTIS AG (CH) | 2012-03-01 | — | — | WO | disclosed |
| EP-0555175-A1 | Biaryl substituted 4-amino-butyric acid amides | CIBA-GEIGY AG (CH) | 1993-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158285-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES FOR THE MANUFACTURE OF NEP INHIBITORS | MME, ACE, DNPEP | MME 1/4885MMEL1 112/4885ACE 2/4885 |
| US-20130158275-A1 | NEW PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE MANUFACTURE NEP INHIBITORS | MME, DNPEP, REN | MME 1/4885MMEL1 51/4885ACE 5/4885 |
| US-11434192-B2 | Process and intermediates | MME, ACE, DNPEP | MME 1/4885MMEL1 120/4885ACE 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.